

News letter

Lund 11 January 2022

Scandinavian ChemoTech continues its focus on Animal Care in the US and prepares for one of the most important trade fairs

The company's CEO plans to conduct a 10-day tour in the United States including being present during the VMX (Veterinary Meeting and Expo), one of the most important trade fairs for veterinary medicine in the United States.

Unless new restrictions or obstacles arise, the Company's CEO, Mohan Frick, will carry out his first trip to the United States since the beginning of the pandemic. During this time, the company has established a number of strategic contacts which we hope to be able to advance further with during these days. The Company continues to have a great outlook on its Animal Care operations in the USA.

"I look forward to meeting potential partners, customers and investors in the USA during a trip that I have long planned to carry out. It feels good to get an updated feeling for the American market ahead of the LSI Emerging MedTech Summit in March 2022, the that I get the chance to get an updated feeling about the America market ahead of the upcoming LSI Emerging MedTech Summit in March 2022. ChemoTech has now for the 3rd year in a row been invited to present its innovations there along with some of the largest MedTech companies and investors. "- says Mohan Frick VD Scandinavian ChemoTech

To read more about VMX: <https://navc.com/vmx/>

To read more about LSI: <https://www.lifesciencemarketresearch.com/medtech-summit-2022>

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se